
ICU Medical (ICUI) Stock Forecast & Price Target
ICU Medical (ICUI) Analyst Ratings
Bulls say
ICU Medical's strong market position as a leader in infusion therapy, bolstered by strategic acquisitions, facilitates a compelling outlook for its financial performance. The company is at the beginning of a new product and pump replacement cycle, which is anticipated to drive revenue growth exceeding 100 basis points, along with an improvement in gross margins by nearly 50 basis points and an EBITDA margin rising above 20%. With a cleaner business structure and enhanced financial profile, ICU Medical could command higher valuation multiples than its current standing, making it an attractive prospect within the medtech sector.
Bears say
ICU Medical faces a significant negative outlook due to its anticipated removal of approximately $35 million in annual EBITDA contribution, which could reduce its leverage below 2x, raising concerns about financial stability and operational efficiency. The profitability of its Vital Care segment is notably weaker, with gross margins (GM%) estimated to be 300-400 basis points lower than its other segments, Consumables and Infusion Systems. This margin disparity suggests potential inefficiencies and underperformance within the Vital Care division, complicating the overall financial attractiveness of ICU Medical amidst ongoing operational challenges.
This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.
ICU Medical (ICUI) Analyst Forecast & Price Prediction
Start investing in ICU Medical (ICUI)
Order type
Buy in
Order amount
Est. shares
0 shares